Artificial intelligence (“AI”) offers unprecedented opportunities to enhance the effectiveness of treatments and significantly reduce drug discovery and development timelines in the pharmaceutical industry. However, existing legal frameworks, including competition law, must be equipped to manage AI-driven innovations effectively. This research underlines the critical and immediate need for the EU to develop regulatory frameworks to adapt to the evolving AI landscape in pharmaceuticals. The s
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 3.135.194.251
Please verify email or join us to access premium content!